A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

← catalyst calendar

NCT03725007 · readout ≤ 865 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

124estimated

Sites

Countries

Canada, Germany, Hungary +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-06-24

actual

When the study began enrolling

Primary completion

Dec 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2029

estimated

The whole study's end, after follow-up

First posted

2018-10-30

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Juvenile Idiopathic Arthritis (JIA)

Intervention

Drug: Upadacitinib — also filed as ABT-494

Primary outcomes

what the primary-completion date above is the date OF

Treatment Emergent Adverse Events (TEAEs)

measured Up to approximately 260 weeks

Part 1: Maximum observed plasma concentration (Cmax)

measured Day 7

Part 1: Time to maximum observed plasma concentration (Tmax)

measured Day 7

Part 1: Area under plasma concentration versus time curve during a dosing interval (AUCtau)

measured Day 7

Part 1: Apparent oral clearance at steady state (CL/F)

measured Day 7

Part 1: Half-life

measured Day 7

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed